Copyright CNW Group 2015
Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
View original source (CNW)Resverlogix Corp. on 6ix
Story so far
Earlier from Resverlogix
- Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference
- Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
- Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum
- Resverlogix Announces Voting Results
- Resverlogix Provides Research and Development Update in New York City
Later from Resverlogix
- Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
- Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman
- The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium
- Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
- Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016
Follow Resverlogix into a list and get an email when it puts out news.
Follow Resverlogix